Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357356 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
A Phase 2 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT01357356 is a Phase 2 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 750 participants.
The verdict
NCT01357356, a Phase 2 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.
Interventions
- DRUG Placebo
- DRUG SER120 (750 ng/day)
- DRUG SER120 (1000 ng/day)
- DRUG SER120 (1500 ng/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01357356
The ClinicalTrials.gov registry entry for NCT01357356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serenity Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01357356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01357356 about?
NCT01357356 is a clinical study titled "Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia". The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.
What is the current status of trial NCT01357356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2011-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01357356?
The interventions under investigation include: Placebo (DRUG), SER120 (750 ng/day) (DRUG), SER120 (1000 ng/day) (DRUG), SER120 (1500 ng/day) (DRUG).
Who is sponsoring clinical trial NCT01357356?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.